Surgery and immunotherapy combo for stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been diagnosed with stomach or gastroesophageal junction cancer that has not spread to other parts of the body.
- Your tumor must show some HER2 protein on its surface (IHC 1+, 2+, or 3+).
- You must not have received any previous treatment for your cancer, including chemotherapy, radiation, or immunotherapy.
- Your overall health must be good enough to undergo surgery, with an ECOG score of 0 or 1.
- Your heart, liver, kidney, and blood cell counts must be within a certain range as determined by lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (targeted therapy, immunotherapy, and chemotherapy) before and after surgery for locally advanced HER2-positive stomach cancer. It aims to see if this treatment can improve outcomes for patients whose cancer has not yet spread.
This trial tests a combination of experimental drugs (IBI343, Sintilimab, and chemotherapy) before and after surgery for a specific type of stomach cancer that is CLDN18.2 positive. The goal is to see if this treatment shrinks the tumor and helps prevent the cancer from coming back.
This trial tests whether adding an immunotherapy drug (QL1706) to a standard chemotherapy regimen, given before surgery, can help shrink stomach or gastroesophageal junction cancer. The goal is to improve the chance of successful surgery and long-term outcomes.
This trial is testing a combination of three medicines—an immunotherapy (anti-PD-1), an immune booster (thymalfasin), and a chemotherapy regimen (SOX)—given before surgery to shrink stage III stomach or gastroesophageal junction cancer and improve outcomes.
This trial tests combining chemotherapy (SOX), an immunotherapy drug (tislelizumab), and low-dose radiation before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination shrinks tumors more effectively.
This trial tests a combination of chemotherapy (DOS) plus an immunotherapy drug (Adebrelimab) given before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if the treatment shrinks the tumor and improves outcomes.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.